Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

While it would not grab as much attention as creating a whole new approval pathway, BIO believes tinkering with accelerated approval to give the regulations more clarity and increase its use still could generate the change it wants at FDA.

You may also be interested in...



PDUFA VI Predictions: Industry Might Pay More, Get More From User Fees

Next iteration of user fee legislation could include reducing amount of data sponsors must collect; 21st Century Cures initiative represents ‘dry run’ that could smooth agreement, Pfizer rep says.

FDA Expanded Access Guidances Fail To Achieve Détente With Advocates

The number of requests to use investigational drugs outside of clinical trials has grown and FDA typically approves all requests, but advocates still insist the process is set up to fail patients.

Recipe For Doubling Innovative Medicines Includes New Approval Pathway, FDA Management Changes

Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel